influenza

influenza
Name	Influenza
Virus group	Orthomyxoviridae
Species	Influenzavirus A; Influenzavirus B; Influenzavirus C; Influenzavirus D
Genome	Segmented negative-sense single-stranded RNA

influenza is an acute respiratory infectious disease caused by viruses of the family Orthomyxoviridae, most notably influenzavirus A and influenzavirus B. It causes seasonal epidemics and occasional pandemics that affect populations worldwide, with substantial morbidity and mortality across age groups. Public health responses involve surveillance, vaccination campaigns, antiviral stockpiles, and non-pharmaceutical measures coordinated by national and international agencies.

Virology

The causative agents belong to the family Orthomyxoviridae and include major species such as Influenzavirus A, Influenzavirus B, Influenzavirus C, and Influenzavirus D. Influenzavirus A subtypes are defined by surface glycoproteins haemagglutinin (HA) and neuraminidase (NA), which undergo antigenic drift and antigenic shift due to point mutations and reassortment, respectively. Viral structure features an enveloped virion with segmented negative-sense RNA genome encoding polymerase complex proteins (PB1, PB2, PA), nucleoprotein, matrix proteins (M1, M2), and accessory proteins such as NS1. Reservoirs and host range include wild aquatic birds for many Influenzavirus A lineages and mammalian hosts such as humans, swine, equines, and avian species. Viral replication occurs in the host cell nucleus, with cap-snatching mechanisms for mRNA synthesis and budding from the apical surface of respiratory epithelial cells.

Epidemiology

Seasonal patterns show peaks in temperate zones during winter months with interseasonal variation influenced by climate, population immunity, and viral evolution. Surveillance networks operated by organizations and laboratories in countries such as the United States, United Kingdom, Japan, Australia, and members of the European Union monitor circulating strains, antigenic properties, and antiviral susceptibility. Pandemic emergence has historically followed zoonotic introductions and reassortment events involving human and animal strains, with notable global spread affected by transportation hubs, urbanization, and public health interventions. Burden estimates incorporate hospital admissions, excess mortality, and economic impact assessed by ministries of health, international agencies, and academic consortia.

Clinical Presentation and Complications

Typical clinical features include abrupt onset of fever, myalgia, headache, sore throat, cough, nasal congestion, and fatigue. Complications range from primary viral pneumonia to secondary bacterial pneumonia with pathogens such as Streptococcus pneumoniae and Staphylococcus aureus, exacerbation of chronic cardiopulmonary conditions, and extrapulmonary manifestations including myositis, myocarditis, and encephalitis in severe cases. High-risk groups identified by public health authorities include older adults, young children, pregnant persons, and individuals with chronic medical conditions. Severe outcomes can necessitate intensive care, mechanical ventilation, and may result in fatality, with excess mortality monitored during epidemics and pandemics.

Diagnosis

Diagnostic approaches include clinical assessment combined with laboratory testing such as rapid antigen detection tests, reverse transcription polymerase chain reaction assays targeting conserved gene segments, direct immunofluorescence, and viral culture in specialized laboratories. Laboratory confirmation is important for surveillance, antiviral susceptibility testing, and guiding treatment in hospitalized or high-risk patients. Diagnostic algorithms used by hospitals, public health laboratories, and reference centers integrate specimen type, timing from symptom onset, and analytic sensitivity to select appropriate assays.

Treatment and Antiviral Therapy

Supportive care, including hydration, antipyretics, and respiratory support as needed, constitutes the foundation of management for uncomplicated cases. Antiviral agents approved for use in humans include neuraminidase inhibitors and polymerase inhibitors; treatment is most effective when initiated early after symptom onset and is recommended for hospitalized patients, those at high risk, and during severe outbreaks. Antiviral resistance surveillance informs clinical guidelines and stockpiling decisions by national authorities and international partners. Adjunctive therapies and clinical trials continue to evaluate immunomodulators, monoclonal antibodies, and novel small molecules.

Prevention and Vaccination

Prevention strategies emphasize annual vaccination programs tailored to circulating strains identified by global surveillance and strain selection processes conducted by international expert panels. Vaccine types include inactivated, live attenuated, and recombinant formulations produced using egg-based, cell-based, or recombinant technologies. Public health campaigns target uptake among priority groups, coordinate logistics with healthcare systems, and rely on recommendations from advisory committees and health ministries. Non-pharmaceutical interventions such as hand hygiene, respiratory etiquette, mask use, and social distancing have roles in outbreak mitigation and were incorporated into responses during major epidemics and pandemics.

History and Public Health Impact

Historic pandemics and major epidemics have shaped public health policy, including events that prompted global coordination, pandemic preparedness planning, and vaccine development. Notable episodes prompted responses from national governments, international organizations, and research institutions, influencing surveillance systems and medical countermeasure stockpiles. Economic disruption, healthcare system strain, and social consequences during severe seasons and pandemics have driven investments in virology research, immunology, and public health infrastructure. Ongoing collaboration among academic centers, public health agencies, and industry seeks to reduce the disease burden through improved vaccines, antivirals, and integrated surveillance.

Category:Orthomyxoviridae